Craig Malbon and his colleagues were convinced that they had made a momentous discovery. So they held a press conference at New York City's Grand Hyatt Hotel to announce it. What they had found, Malbon told reporters last week, was an enzyme that acts as the master switch for breast cancer, a disease that kills 44,000 women in the U.S. each year. "This gives us a new diagnostic tool and a new therapeutic strategy," maintained Malbon, a pharmacologist at the State University of New York at Stony Brook.
Or does it? What the SUNY team found was that some breast-cancer cells...
To continue reading:
or
Log-In
